ACRS - Aclaris Therapeutics, Inc.
| Previous Close | 17.69 |
| Open | 17.66 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 17.36 - 17.95 |
| 52 Week Range | 16.01 - 30.08 |
| Volume | 201,478 |
| Avg. Volume | 306,608 |
| Market Cap | 549.12M |
| Beta | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.17 |
- GlobeNewswire•17 hours ago
Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
WAYNE, Pa., April 24, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
- GlobeNewswire•17 hours ago
Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced the appointment of Bryan Reasons as a director and Chairman of the Audit Committee. Bryan Reasons has served as the Senior Vice President, Finance and Chief Financial Officer of Impax Laboratories Inc. since 2012. Prior to joining Impax, Mr. Reasons was with Cephalon, Inc., a biopharmaceutical company, serving as Vice President, Finance from 2010 to 2011 and as Vice President, Risk Management and General Auditor from 2005 to 2010.
- GlobeNewswire•2 days ago
Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
WAYNE, Pa., April 23, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
- GlobeNewswire•7 days ago
Investor Expectations to Drive Momentum within Casella Waste, Prologis, Flushing Financial, AMERISAFE, Aclaris Therapeutics, and NanoString Technologies — Discovering Underlying Factors of Influence
NEW YORK, April 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- CNW Group•19 days ago
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics
- GlobeNewswire•19 days ago
Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada
The agreement will expand the availability of the first and only U.S. FDA-approved prescription product for the treatment of raised seborrheic keratoses. WAYNE, Pa., April 06, 2018-- Aclaris Therapeutics, ...
- GlobeNewswire•22 days ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., April 03, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to ...
- GlobeNewswire•27 days ago
Analysis: Positioning to Benefit within TopBuild, MarketAxess, Provident Financial Services, SailPoint Technologies, Aclaris Therapeutics, and VOXX International — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- ACCESSWIRE•last month
Blog Exposure - Aclaris Therapeutics Shares Positive Update on Phase-2 Results after a 3-Month Follow-Up of A-101 45% Topical Solution
Stock Monitor: Aurinia Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Aclaris Therapeutics, Inc. (NASDAQ: ACRS ...
- GlobeNewswire•last month
Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine
WAYNE, Pa., March 20, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant ...
- GlobeNewswire•last month
Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
Primary, secondary, and exploratory endpoints of Phase 2 trial met during 8- week treatment period After treatment completed, greater improvement vs. placebo observed in 3- month post-treatment follow-up ...
- American City Business Journals•last month
Aclaris experimental hair loss treatment gets additional patent protection
A new drug candidate being developed by a Chester County biopharmaceutical company to treat hair loss disorders has received additional patent protection. The U.S. Patent and Trademark Office issued the patent, which covers methods related to the use and administration of a certain janus kinase [JAK] inhibitor, to the trustees of Columbia University in New York City. Columbia has exclusively licensed the JAK inhibitor to Aclaris Therapeutics of Malvern, Pa., in connection with the company's JAK drug development program for hair loss disorders.
Motley Fool•last monthAclaris Therapeutics (ACRS) Q4 2017 Earnings Conference Call Transcript
ACRS earnings call for the period ending December 31, 2017.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ACRS earnings conference call or presentation 12-Mar-18 12:00pm GMT
Q4 2017 Aclaris Therapeutics Inc Earnings Call
- Associated Press•last month
Aclaris reports 4Q loss
On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 74 cents. Losses, adjusted for pretax gains, came to 80 cents per share. The results beat Wall Street expectations. The ...
- GlobeNewswire•last month
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments
Initiates Financial Guidance for Full Year 2018 Management to Host Conference Call at 8:00 AM ET today. WAYNE, Pa., March 12, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company ...
- ACCESSWIRE•last month
Aclaris Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 8:00 AM Eastern ...
- American City Business Journals•2 months ago
Aclaris experimental hair loss treatment gets additional patent protection
The Chester County biopharmaceutical company has an exclusive license from Columbia University for the new drug candidate.
- GlobeNewswire•2 months ago
Aclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders
Patent No. 9,895,301 Further Bolsters Aclaris’ Intellectual Patent Portfolio. WAYNE, Pa., March 09, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, ...
- GlobeNewswire•2 months ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., March 06, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to ...
- GlobeNewswire•2 months ago
Aclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018
WAYNE, Pa., Feb. 28, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to ...
- Motley Fool•2 months ago
Could These 2 Biotech Stocks Really Double Your Money?
Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
- GlobeNewswire•2 months ago
Aclaris Therapeutics to Present Data on ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting
ESKATA™ received FDA approval for the treatment of raised seborrheic keratoses in December 2017. WAYNE, Pa., Feb. 08, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, today ...
- GlobeNewswire•3 months ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MALVERN, Pa., Feb. 05, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to ...
- GlobeNewswire•3 months ago
Aclaris Therapeutics to Attend Upcoming Investor Conferences
MALVERN, Pa., Feb. 02, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to ...
